isoxazoles has been researched along with dactolisib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, PM; Chao, Y; Chen, MH; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Huang, CY; Huang, SC; Jan, YY; Li, CP; Liu, CY; Wang, HM; Weng, JJ; Yeh, CN; Yeh, TS | 1 |
1 other study(ies) available for isoxazoles and dactolisib
| Article | Year |
|---|---|
Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Proliferation; Cholangiocarcinoma; Female; Flow Cytometry; Follow-Up Studies; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Immunoenzyme Techniques; Isoxazoles; Male; Membrane Potential, Mitochondrial; Middle Aged; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinolines; Rats; Rats, Sprague-Dawley; Resorcinols; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |